Skip to Main Content

Paper Details

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
European urology oncology
4
2022
Cancer, MIUC, Muscle-invasive Urothelial Carcinoma, Nivolumab, PD-1, PD-L1, bladder cancer, cancer, fatigue, muscle-invasive urothelial carcinoma, nivolumab, patients, platinum, programmed death ligand 1, programmed death-1, urothelial carcinoma
Author NameAffiliation
Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 1

Datasets

Release 1.2